Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Factbox lists recent licensing deals between major drugmakers and Chinese biotechs, including Novo Nordisk's pact with Jiangsu Hengrui for an experimental weight-loss pill. It also cites several deals involving Merck, Pfizer, Eli Lilly, Bristol Myers Squibb, GSK and Roche.
Novo Nordisk OMXCOP:NOVO_B said on Tuesday it will pay up to $2.6 billion to Jiangsu Hengrui Pharmaceuticals SSE:600276 for the rights to an experimental weight-loss pill, making it the latest drugmaker to license China-developed medicines.Chinese biotechs often retain domestic rights and license t…
Merck agreed to pay Chinese biotech SciBrunch Therapeutics $400 million upfront for global rights to an experimental cancer drug.